A new weapon in the fight against osteoarthritis?
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating osteoarthritis. This is based on a polysaccharide, a long-chain sugar molecule, originating from brown algae. When chemically modified, this “alginate” reduces oxidative stress, has an anti-inflammatory effect in cell culture tests and suppresses the immune reaction against cartilage cells, thereby combating the causes of arthritis. The research is, however, still in its infancy.
Osteoarthritis is the most-widespread joint disease, with around 90 percent of all people over 65 being affected to varying degrees, but this degenerative disease is also widespread amongst younger people. In arthritis, the cartilage in the joint, a type of protective layer on bones that “lubricates” the joint, degenerates over time. This can be extremely painful for sufferers, because inflammatory reactions are associated with cartilage degeneration. In the later stages of the disease, bones are no longer adequately protected and can directly rub against each other.
Osteoarthritis can affect all joints in the body, but most often affects the knee joint, hip joint and fingers. The disease has been considered incurable until now. Current treatment methods, such as anti-inflammatory drugs and painkillers, mainly address the symptoms. Often, the only remaining option is an operation to replace the affected joint with an artificial one.
Initial research results are encouraging
In laboratory tests, the team led by ETH researcher Marcy Zenobi-Wong and Empa researcher Katharina Maniura has now succeeded, together with SINTEF in Norway, in identifying a substance with the potential to halt cartilage degeneration in joints. This substance is the polysaccharide alginate extracted from the stems of brown algae – or more precisely cuvie (Lat. Laminaria hyperborea), which is similar to specific extracellular biomolecules in cartilage. The researchers chemically modified the alginate with sulfate groups and then added it in dissolved form to cell cultures to examine the reaction of various cell types to the modified polysaccharide. This revealed that alginate sulfate can significantly reduce oxidative stress, which is a frequent cause of cell damage or even cell death, and the more sulfate groups attached to the alginate molecule, the greater this reduction.
Alginate sulfate was also able to suppress the inflammatory reaction, again depending on the number of sulfate groups, and was able to down-regulate the expression of genes that trigger an inflammatory reaction in both human cartilage cells, known as chondrocytes, and in macrophages, the “scavenger cells” of our immune system. The algal molecules should therefore slow down cartilage degeneration. “The hope is that they can even stop this degeneration,” says Empa researcher Markus Rottmar.
Further research work necessary
The alginate sulfates have so far only been tested in vitro, i.e. in the laboratory with cell cultures. However, the encouraging results mean that research will now continue. The next stage is to test the substances on animals. If this is also successful, clinical trials can then be conducted on people. These tests are, however, laborious and time-consuming. If everything were to work perfectly, it would still be a few years before arthritis patients could be treated with alginate sulfate.
Learn more: Treating arthritis with algae
The Latest on: Osteoarthritis
- Zoetis Receives European Commission Marketing Authorization for Solensia®(frunevetmab), a New Therapy for Feline Osteoarthritis Painon February 22, 2021 at 9:40 am
Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia® (frunevetmab), a new ...
- Kessler Team tests regenerative approach to preventing osteoarthritis after knee injuryon February 22, 2021 at 8:44 am
Osteoarthritis of the knee is one of the most common causes of disability among service members who are medically separated from active duty. ''We anticipate that regenerative interventions will ...
- Zoetis’ Osteoarthritis Therapy For Cats Authorized In Europe; Street Sees 26% Upsideon February 22, 2021 at 4:38 am
Solensia is developed as a therapy to relieve osteoarthritis pain in cats. Osteoarthritis has a high prevalence rate in cats affecting about 40%. It can generate pain and may reduce quality of life if ...
- Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacyon February 17, 2021 at 12:54 pm
Despite encouraging results reported with regards to Platelet-rich plasma (PRP) application in osteoarthritis (OA) knee, still critical issues like conclusive structural evidence of its efficacy, ...
- High-intensity strength training no added benefit for knee osteoarthritison February 17, 2021 at 7:54 am
High-intensity strength training does not significantly improve knee pain with osteoarthritis compared with low-intensity strength training or a control condition, according to a study published in ...
- Moebius Medical Announces Dosing of First Patient in Global Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Painon February 16, 2021 at 3:20 pm
Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel ...
- Akan Biosciences Announces FDA Acceptance of IND Application for StroMel™ in Osteoarthritis of Kneeon February 16, 2021 at 3:56 am
StroMel™ is a proprietary adipose-derived Stromal Vascular Fraction (SVF) product. StroMel™ will be frozen and stored allowing multiple administrations with each lot. Although the current IND is for ...
- Water Cycling Reduces Osteoarthritis Pain in Kneeson February 15, 2021 at 5:44 am
PRNewswire/ -- "One doesn't often think of cycling and water together," says Paradise's Starr Nixdorf, ATRIC, "but that's just what we do in our therapy ...
- Common Antidepressant Could Represent First Disease-Modifying Treatment for Osteoarthritison February 11, 2021 at 5:00 am
Researchers are seeking FDA approval to start clinical trial assessing paroxetine in the treatment of osteoarthritis.
- Common anti-depressant may be first-ever treatment for osteoarthritison February 10, 2021 at 11:03 am
A disease of the joints, osteoarthritis affects more than 30 million adults and is the fifth-leading cause of disability in the United States. In a new study, scientists have discovered the cellular ...
via Google News and Bing News